Therapia Hungarica (English edition)最新文献

The effect of 2 sodium chromoglycate products: Taleum 1-mg aerosol (EGIS) and Intal powder capsule (Fisons) has been examined for 4-4 weeks in 15 extrinsic asthma patients by cross-over self-controlled open method. The patients measured peak expiratory flow (PEF) 5 times daily and recorded the time of dyspneic periods in a diary as well as the amount of bronchodilator spray (Berodual, Boehringer) used as adjuvant therapy during dyspnea. The results of the weekly evaluation of the complaints and PEF values proved that both drugs are similarly effective in the prevention of dyspnea caused by bronchial asthma. The adjuvant inhalation betamimetic and anticholinergic drug requirement was lowered, the number, intensity and total time of dyspneic episodes decreased. In the course of the examinations Taleum 1-mg inhalation aerosol proved to be of identical value with Intal powder capsule. Some patients who do not like powder inhalation found the Taleum aerosol drug form to be more advantageous. Side-effect of drug was not observed.

Observations with Melipramine (imipramine) coated tablet used in the treatment of bladder instability are reported. The patients were selected on the basis of urodynamic examinations. Five men and 45 women were treated for 2 and 4 weeks. The patients recorded the number of urinations and urgency as well as the quantity of voided urine. The effectivity of treatment was controlled by urodynamic examinations. Melipramine (3 x 2 coated tablet) given in 60-mg daily doses, favourably influenced the symptoms. The effectivity of treatment reached 90% in the selected patients. Side-effects developed in 5 cases: in 3 patients the treatment had to be discontinued because of palpitation, feeling weakness. According to the authors' opinion Melipramine is a useful therapeutic means in the treatment of bladder instability.

The results of our study prove--incongruency with data in references--that pefloxacin, Pèflacine (EGIS-Rhône-Poulenc-Rorer) can be successfully used in the treatment of severe, medium severity infections acquired in hospitals. Our observations refer to urinary tract, hepatic-biliary tract, and lower respiratory tract infections. Differences were not found between the effectivity of oral and intravenous drug doses. Side-effects were observed in a relatively low number of cases, in 10% of the patients. On the basis of our observations pefloxacin seems to be an effective drug which can be used safely.

The effect of the angiotensin-converting enzyme inhibitor, Tensiomin, has been examined in patients suffering from ischaemic dilatative cardiomyopathy who had become unresponsive to combined vasodilatator--diuretic--digitalis therapy. The results were evaluated according to the changes in NYHA classes and echocardiographic parameters. Significant improvement was observed in response to Tensiomin in 38 of the 52 patients (73%). On the basis of the results the use of captopril (Tensiomin) is highly recommended for the treatment of ischaemic dilatative cardiomyopathy.

The authors examined the lipid-peroxide (malondialdehyde) blood concentration of patients suffering from rheumatoid arthritis of osteoarthrosis. Of the anti-oxidant compounds, they examined the vitamin E concentration of blood plasma and catalase as well as glutathione-peroxidase enzyme activities. They also measured the oxidation capacity of blood plasma. It has been observed that the functional condition of patients in both disease groups improved following a 14-day treatment (20 md/day Hotemin). The degree of lipid-peroxidation (malondialdehyde content) as well as plasma oxidation capacity decreased in patients with osteoarthrosis, while these values did not change in patients suffering from rheumatoid arthritis. When examining the anti-oxidant enzymes in rheumatoid arthritis, a significant change was observed in glutathione-peroxidase activity. On the basis of the results it may be concluded that piroxicam has no direct anti-inflammatory action, but as an anti-oxidant, it exerts an action which is disease specific.

In 60 insomnia patients placebo-controlled clinical examinations were performed with Dormicum hypnotic containing 15 mg midazolam active substance and made available by EGIS Pharmaceuticals. The patients involved in the study lived a normal life and belonged to both sexes. In the introduction the author summarizes the different forms of pathological sleep and discusses the pharmacology of some hypnotics on the basis of which a detailed, multifactorial, up-to-date clinical examination of a hypnotic should be planned. He uses up-to-date methods and means for the examination of the drug which meet the requirements of an adequate clinical testing of a hypnotic. The sleep disturbances of the patients have been classified and characterized by the author from the somnological aspects and with somnological methods. Patients with sleep onset, sleep maintenance, early morning, as well as mixed insomnias were differentiated. The effectivity of the drug was evaluated on the basis of data of sleep questionnaires referring to the target symptoms and the results of 24-hour polygraphic monitorings performed in 18 patients. In addition, the eventual hangover effect of the drug was assessed in these patients on the basis of the changes in reaction time, pulse rate, and skin resistance measured by polygraphy, besides placebo control on the day following the intake of the drug. The neurological and other organic side-effects were also examined and registered by means of the self-evaluating questionnaires, target specific interviewing of the patients, as well as by laboratory examinations. The drug proved to be most valuable as a hypnotic in patients with sleep onset and mixed insomnias. The hypnotic action was not so definite in sleep maintenance insomnias, the poorest responses were obtained in early morning insomnia cases. According to the results of polygraphic sleep examinations the two first sleep cycles become normal following the intake of the hypnotic. Parameters characteristic of REM sleep do not show changes. In the examined patients the number of side- and hangover effects attributable to the drug was very low. The author calls the attention to the importance of the observance of the dosage and administration of the drug which may prevent the development of a great number of side-effects. By giving a detailed description of a case history of an insomniac patient the author illustrates how the application field of midazolam may be further extended--within the frames of a sleep therapeutic process.

The effect of coated Mydocalm tablet, given in 3 x 150-mg daily doses for 3 weeks to 47 patients, simultaneously with physiotherapy, has been examined in comparison to the results of 47 patients treated with physiotherapy solely. In the group of patients receiving Mydocalm as an adjuvant to physiotherapy the alleviation of pain and moderation of muscular hypertonia and spasm were observed within a shorter period. On the basis of the results of these examinations the use of Mydocalm is recommended as an adjuvant to complex therapy, in 300-450-mg daily doses, for the treatment of locomotor diseases accompanied by muscular hypertonia, muscular spasticity, and contracture.

The efficacy of Cordaflex (EGIS) and Adalat (Bayer), both containing 10 mg nifedipine, has been examined in ischaemic cardiopathic patients. The fifteen ischaemic cardiopathic patients were treated with identical doses of Cordaflex and Adalat, simultaneously with unchanged nitrate and beta-blocker therapy. The patients received 30-80-mg identical nifedipine doses daily for 1 week each. In 13 patients change was observed neither in the weekly nitroglycerin consumption nor in the time or intensity of silent and active ischaemic periods registered with 24-hour ECG monitoring. Significant change was observed in one patient during Cordaflex administration, in another patient during Adalat therapy. However, these changes were attributed either to the progression of, or to the spontaneous improvement in the primary disease. Considering the effect influencing blood pressure and heart rate, and one side-effect, there was no difference between the two products. The anti-ischaemic effect of Cordaflex and Adalat was found to be identical.